TargED Biopharmaceuticals

TargED Biopharmaceuticals is dedicated to pioneering advancements in pharmaceutical manufacturing, specifically focusing on targeted enzyme delivery to improve thrombolysis. With a commitment to innovation, TargED Biopharmaceuticals is actively developing MICROLYSE, a biopharmaceutical product designed to enzymatically break down blood clots in small blood vessels, also known as the microvasculature.

TargED Biopharmaceuticals aims to address critical unmet needs in the treatment of microvascular thrombosis, with a focus on obtaining market authorization for Thrombotic Thrombocytopenic Purpura (TTP), an orphan disease characterized by life-threatening microvascular thrombosis attacks. The company's headquarters is located in Utrecht, at Princetonlaan 6, 3584 CB, NL. TargED Biopharmaceuticals is poised to make a significant impact on patient outcomes through its innovative approach.

TargED Biopharmaceuticals is committed to expanding the applications of MICROLYSE to target all forms of microvascular thrombosis, including early-stage macrovascular thrombosis as seen in heart attacks and strokes. We invite the management of TargED Biopharmaceuticals to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.